Steven Yates, MD, an oncologist and medical director at Intermountain Healthcare, discusses problems underlying the 340B Drug Pricing Program.
The Center for Biosimilars® interviewed Steven Yates, MD, a medical oncologist and medical director at Intermountain Healthcare in Las Vegas, Nevada. Three years ago, Intermountain hired him to lead its biosimilar adoption effort.
Dr Yates expresses distaste for the 340B Drug Pricing Program, calling it a “disaster for community oncology” because it has contributed to a reduction in community oncology practices across the country over the years. The 340B program has given hospitals an unfair advantage, enabling them to acquire physician-led practices, he says. In many cases savings from the program have not benefited paitents. Ironically, Yates says, 340B hospitals have been very slow to adopt biosimilars, instead preferring reference products at prices that are higher on average than biosimilar prices.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?